New research indicates that individuals who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional lifestyle plans.
Findings released in a major health publication demonstrates that while obese people often shed a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users using such medications must be informed of the potential of fast weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment weight in about a year and a half.
Comparing Approaches
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting typically see a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Doctors propose the mechanism of the jabs explains the accelerated weight return.
The injections copy a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of weight regain, the therapy is often long-term.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
People who have come off the medication explain a sudden resurgence of cravings.
"I experienced a switch activating and you become extremely hungry," said a patient.
This challenge is compounded if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Figures show that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while the jabs are powerful agents for weight loss, they are not a permanent fix and long-term success hinges on integrated behavioural support.
